Evaluation of latent membrane protein 1 and microRNA‑155 for the prognostic prediction of diffuse large B cell lymphoma

Authors:

Abstract
Diffuse large B cell lymphoma (DLBCL) has previously been demonstrated to contribute to the mortality of lymphoma with various aggressive features. The prognostic role of the biomarkers latent membrane protein (LMP) 1 and microRNA‑(miR)‑155 in DLBCL remain controversial. The present study primarily aimed to assess the effect of LMP1 and miR‑155 on the survival of DLBCL patients, and additionally evaluate the clinical features to observe their influence on outcomes, compared with previous studies. Formalin‑fixed and paraffin‑embedded samples were collected from our center between May 2010 and December 2011. Microarray analysis, immunohistochemical analysis and reverse transcription-quantitative polymerase chain reaction were used to evaluate the expression of LMP1 and miR‑155. The association between biomarkers or clinical features and patient outcomes was assessed using the log‑rank statistical test, Cox proportional hazard model and Kaplan‑Meier method. SPSS software was used to statistically analyze the data. A total of 82 patients were included in the present study. The results demonstrated that high expression of LMP1 and miR‑155 may be associated with a poor progression‑free survival rate, while a high International Prognostic Index score and high expression of LMP1 may be associated with a poor overall survival rate. These results indicated that LMP1 and miR‑155 may be novel and reliable biomarkers for the prognostic prediction of lymphoma, and will potentially be analyzed in the future to evaluate patient prognosis.

This publication has 36 references indexed in Scilit: